MedTrace Logo

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

NCT06565546 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-01

No results posted yet for this study

Summary

Pilot pragmatic trial using an implementation science approach to determine the feasibility of a CYP2D6-guided opioid prescribing for patients undergoing elective VHRs compared to usual care. Assess the efficacy (PROMIS Pain Intensity and Hernia-Related QOL) of a CYP2D6-guided opioid prescribing approach for patients undergoing elective VHRs.

Conditions

  • Ventral Hernia

Interventions

OTHER

Acetaminophen and Gabapentin: standard postoperative pain medications

Participants will receive standard postoperative pain medications

OTHER

Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin

CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Jana Sacco, MD · Assistant Professor

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-29
Primary Completion
2026-06-01
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06565546 on ClinicalTrials.gov